HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Annora Pharma Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Annora Pharma Intelligence Report

Generated from 7 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Aug 8, 2026

Confidence

Moderate Confidence · 74%

Evidence

42 items

Sources

14

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Annora Pharma maintains an active intelligence profile across Cardiology, Diuretic, Neurology, Antiepileptic, Rare Diseases. 7 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 74% across 3 tracked sources. Highest-priority development: FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. Regulatory precedent. Why this matters: sets a approval precedent in the same sub-indication (cardiology) as Annora Pharma; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA TA — NDA220613

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — BAXFENDY (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA AP — OXCARBAZEPINE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    Wizcure Pharmaa Private Limited - 726378 - 06/24/2026

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    Unique Pharmaceutical Laboratories (A Div.

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    Internet Pharmacy Warning Letters

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    Oncology (Cancer)/Hematologic Malignancies Approval Notifications

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    Withdrawn | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 335 with buyer quality 7 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA TA — NDA220613

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BAXFENDY (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — OXCARBAZEPINE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Wizcure Pharmaa Private Limited - 726378 - 06/24/2026

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Unique Pharmaceutical Laboratories (A Div.

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Internet Pharmacy Warning Letters

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Oncology (Cancer)/Hematologic Malignancies Approval Notifications

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Withdrawn | Cancer Accelerated Approvals

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Verified Clinical Benefit | Cancer Accelerated Approvals

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Rare Disease Drug Approvals

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Grants AP Status for Spironolactone ANDA217761 by Annora Pharma

    Cardiology · Diuretic

  • FDA Accepts Supplement for OXCARBAZEPINE by Annora Pharma

    Neurology · Antiepileptic

  • FDA Grants Approval for L-Glutamine ANDA219722 by Annora Pharma

    Rare Diseases · Urea Cycle Disorders

  • FDA Grants AP Status for Desogestrel and Ethinyl Estradiol ANDA219670

    Women's Health · Contraceptive

  • FDA Grants Approval for Fostamatinib Disodium ANDA217329

    Hematology · Spleen Tyrosine Kinase Inhibitor

  • FDA Grants AP Status for Spironolactone ANDA217761 by Annora Pharma

    Cardiology · Diuretic

  • FDA Grants Approval for Diphenhydramine Hydrochloride ANDA219470

    Allergy · Antihistamine

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.